Sector News

AstraZeneca sells migraine drug for up to $302 million

June 8, 2017
Life sciences

AstraZeneca continued its program of divesting old medicines on Wednesday with the sale for up to $302 million of migraine drug Zomig to Germany’s Grunenthal.

The British firm, which is betting on new drugs for cancer and other diseases to revive its fortunes, has sold or licensed out a raft of aging products recently. Some analysts have criticized the trend for unduly propping up its earnings.

Grunenthal will acquire global rights to Zomig in all markets outside Japan, paying AstraZeneca $200 million upon completion of the deal. AstraZeneca will also receive up to $102 million in future milestone payments.

In 2016, AstraZeneca’s revenue from Zomig outside Japan was $96 million.

The two companies added that Impax Pharmaceuticals, which had previously licensed rights to the drug in the United States, would continue to sell Zomig in that market.

For Grunenthal – best-known as the company that initially developed thalidomide as a morning sickness drug – the acquisition builds up its growing business in pain products.

Chief Executive Gabriel Baertschi said it was an important step in reaching the group’s ambition to become a company with 2 billion euros ($2.25 billion) of sales by 2022. Sales in 2016 totaled around 1.4 billion euros.

Like other recent drug divestments, the Zomig agreement does not impact AstraZeneca’s financial guidance for 2017.

By Ben Hirschler

Source: Reuters

Related News

October 17, 2020

Ong leaves Biogen to become CEO-partner at Flagship

Life sciences

The appointment makes Tuyen Ong the latest in a series of new CEO-partners hired by Flagship. Flagship Pioneering has named Tuyen Ong as CEO-partner. The new role sees the ex-Biogen […]

October 17, 2020

Pharma, take note: Millennials plan to spend more on meds, study says

Life sciences

The COVID-19 pandemic has millennials worried—and that has them planning to buy more prescription drugs in the future, new research finds. WPP’s global media group, Mindshare, began surveying consumers in […]

October 17, 2020

AstraZeneca secures $486m from US for Covid-19 antibody

Life sciences

AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment. AstraZeneca has received an investment […]